Welcome
BioPheresis GmbH, a bio-medical technology company focused on tumour immunotherapy, has developed a novel technology and proprietary medical device for the treatment of cancer.
The BioPheresis OncoSorb® therapy is, as the name of the Company suggests, a form of therapeutic apheresis, an extracorporeal blood filtration therapy comparable to dialysis. It removes specific cancer-protecting immune-inhibitors from the blood, thus enhancing the body’s natural immune system and allowing it to destroy the tumour.
News
July 2010
BioPheresis and Cytologic Close Settlement and License Agreements, Enter Research Collaboration
October 2009
BioPheresis Appoints Niels Emmerich as Chief Executive Officer.
More ...
April 2008
Biopheresis’ OncoSorb® column receives CE mark.
More ...
